Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BMS-986504 plus nab-paclitaxel/gemcitabine versus placebo plus nab-paclitaxel/gemcitabine in untreated metastatic MTAP-deleted pancreatic ductal adenocarcinoma
PACTR202606701100493Phase 2Recruiting
- Sponsor
- Bristol Myers Squibb
- Start
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of MRTX1719 in pancreatic adenocarcinoma (PDAC) (4 arms), sponsored by Bristol Myers Squibb. Started Nov 2025; status: recruiting.
02
Drugs
MRTX1719
03
Conditions
pancreatic adenocarcinoma (PDAC)
Beyond the preview
Go deeper on PACTR202606701100493.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202606701100493.